Using biomarkers to guide secondary prevention in ischemic stroke

Mira Katan, MD, MSc, FESO, University Hospital and University of Basel, Basel, Switzerland, talks on the use of biomarkers to individualize secondary prevention in ischemic stroke. Dr Katan explains that stroke is a heterogeneous disease with various causes, including embolic events, atherosclerosis, vasculitides, and arterial dissection. Identifying the exact cause is challenging, with up to 25-30% of cases remaining unexplained despite thorough investigation. Biomarkers could play a crucial role in pinpointing these underlying causes, leading to more personalized secondary prevention strategies. Dr. Katan also discusses the ongoing Moses trial, which uses a biomarker (MRproANP) to guide preventive treatment decisions, aiming to improve outcomes by targeting the specific physiological mechanisms behind stroke. This interview took place at the 10th European Stroke Organisation Conference (ESOC) 2024 in Basel, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.